<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A patient is described in whom treatment with the cholesterol-lowering agent <z:chebi fb="0" ids="40303">Lovastatin</z:chebi> (Mevacor <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSD</z:e>) led to a slight to moderate elevation of amylase and <z:chebi fb="0" ids="16990">bilirubin</z:chebi> with the occurrence of symptoms attributable to mild <z:hpo ids='HP_0001733'>pancreatitis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>These symptoms were sufficiently severe to require discontinuation of the drug </plain></SENT>
<SENT sid="2" pm="."><plain>The concomitant existence of <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> in this patient may have been causally related to the non-tolerance of this valuable drug </plain></SENT>
<SENT sid="3" pm="."><plain>Although a penetrating <z:mpath ids='MPATH_579'>ulcer</z:mpath> cannot be ruled out in the differential diagnosis, the overall evidence favours the diagnosis of <z:chebi fb="0" ids="40303">Lovastatin</z:chebi> <z:hpo ids='HP_0001733'>pancreatitis</z:hpo>, a so far unpublished complication </plain></SENT>
</text></document>